Key result
Pretreatment with 2 g intravenous vitamin C did not significantly reduce the levels of CK-MB (P=0.826) or troponin (P=0.821) 24 hours after coronary artery bypass graft compared to placebo.
Why the study?
Coronary artery bypass graft is associated with oxidative stress and tissue damage, and vitamin C might have cardioprotective effects.
Does intravenous vitamin C pretreatment reduce cardiac biomarker release in patients undergoing CABG?
RCT (n=122)
Double-blind
randomly assigned
Does intravenous vitamin C pretreatment reduce cardiac biomarker release in patients undergoing CABG?
p-value: p=0.826 for CK-MB, 0.821 for troponin
Pretreatment with 2 g of intravenous vitamin C does not reduce myocardial injury biomarkers (CK-MB, troponin) or improve total antioxidant capacity 24 hours after CABG surgery.
Does not support intravenous vitamin C pretreatment in CABG; confirms neutral effect on myocardial biomarkers in this setting.
Background: Coronary artery bypass graft (CABG) is associated with oxidative stress and tissue damage. Vitamin C, as an antioxidant agent, has an important role in attenuating the oxidative stress damage and might have cardio-protective effects after CABG. We aimed to evaluate the probable roles of vitamin C supplementation in cardiac biomarkers after CABG. Methods:: In this randomized control trial, 122 patients undergoing CABG were randomly assigned to the intervention (n=54) and control group (n=68) and received vitamin C (2 g intravenously) or placebo, respectively. The surgical methods of the patients in the two groups were identical. The primary efficacy endpoint of this trial is the difference in the levels of CK-MB, Troponin and Total Antioxidant Capacity (TAC) were measured at study entry and 24 hrs after surgery between the two groups. Results:: The two groups were not significantly different in terms of basic variables. Within-group comparison showed significant rises in the level of troponin (P < 0.001) and CK-MB (P < 0.001) over time. However, between-group comparison showed no significant difference between the two groups in terms of CK-MB (P=0.826) and troponin (P=0.821). As a whole, the correlation between cardiac enzymes and surgical characteristic was not seen. Conclusion:: The results showed that pretreatment with vitamin C could not reduce cardiac marker following CABG. After the intervention, TAC did not differ between and within the intervention and the control groups. Pretreatment with vitamin C as an antioxidant agent could not reduce ischemicreperfusion resulting in CABG.
No takes yet. Share an insight, caveat, or question.
Moludi et al. (2020) conducted an RCT in Coronary artery bypass graft (CABG) (n=122). Vitamin C vs. Placebo was evaluated on Difference in the levels of CK-MB, Troponin and Total Antioxidant Capacity (TAC) measured at study entry and 24 hrs after surgery (p=0.826 for CK-MB, 0.821 for troponin). Pretreatment with 2 g intravenous vitamin C did not significantly reduce the levels of CK-MB (P=0.826) or troponin (P=0.821) 24 hours after coronary artery bypass graft compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: